コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 cells expressing the cardiac mesoderm marker KDR(+).
2 luorobutane-containing lipid-shelled MBs (MB(KDR)).
3 n of the VEGF receptor VEGFR2 (also known as KDR).
4 elial growth factor receptor-2 (VEGFR2/Flk-1/KDR).
5 ctor receptor-2 (VEGFR2/fetal liver kinase 1/KDR).
6 r methylation of VEGF genes (FLT4, FLT1, and KDR).
7 ring these predicted deleterious variants in KDR.
8 ane regions can each confer association with KDR.
9 providing evidence for direct involvement of KDR.
10 e receptor with strong homology to mammalian KDR.
12 Silencing of ECSCR disrupts VEGF-induced KDR activation and AKT and ERK phosphorylation and impai
14 ctivation of KDR/PLCgamma1 signaling besides KDR activation in angiosarcomas, with implications for V
15 -1,4-benzoxazines as inhibitors of intrinsic KDR activity (IC 50 < 0.1 microM) and human umbilical ve
17 ever, there was a strong correlation between kdr allele expression and the levels of insecticide resi
19 a systematic study of resistance-associated kdr allelic expression within and among resistant and su
22 regulation of kinase insert domain receptor (KDR), also known as VEGFR2, in a myeloid cell sublineage
23 fixed (>= 90%) in all villages but the 1575Y kdr-amplifying mutation was relatively rare (< 15%).
24 ater binding specificity of MB(KDR) to human KDR and cross-reactivity to murine VEGFR2 (P < or = .01)
26 also disrupted complexation between NRP1 and KDR and decreased VEGF-dependent phosphorylation of foca
27 sponding to the autophosphorylation sites of Kdr and developed a simple, robust, high-throughput assa
32 Hypoxia induced tyrosine phosphorylation of Kdr and Flt1 in mouse retina, and depletion of Kdr or Fl
33 indings suggest that although VEGFA, through Kdr and Flt1, appears to be the major modulator of Src-P
37 f multiple independent origins of kdr, super-kdr and kdr-his on an unprecedented geographic scale.
39 e transcription, positively of proangiogenic KDR and negatively, in part, of antiangiogenic SFRP4 Twi
40 s of ROR2(+) cells and diffuse expression of KDR and PDGFRalpha in first-trimester human fetal hearts
42 carrying both endothelial progenitor (CD34, KDR) and osteoblastic (osteocalcin [OCN]) cell surface m
44 (PGF); VEGF receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4); and the gene encoding pigment e
45 oximately 2-fold) in the percentage of CD34+/KDR+ and CD34+/CD133+/KDR+ cells costaining for OCN.
46 er of circulating CD34+, CD34+/AC133+, CD34+/KDR+, and CD34+/AC133+/KDR+ progenitor cells was low in
47 enes involved in angiogenesis such as FLT-1, KDR, and angiopoietin 2 have potential E2F1 binding site
49 ar endothelial growth factor (VEGF) receptor KDR, and genes involved in angiogenesis (LRP5, FZD4) on
54 hrombin (vascular endothelial growth factor, KDR, Ang-2, matrix metalloproteinase 1, GRO-alpha, and C
56 el and observed that both anti-VEGF and anti-KDR antibodies inhibit the transmigration of both CD4(+)
58 ic mutations in Vssc (kdr, kdr-his and super-kdr) are known to cause resistance to pyrethroid insecti
59 ase results from a reduced potassium current Kdr as a result of accumulation of periaxonal potassium
62 domain-containing receptor tyrosine kinase (KDR) both enzymatically (<10 nM) and cellularly (<10 nM)
63 how that ECSCR biochemically associates with KDR but not FLT1 and that the predicted ECSCR cytoplasmi
64 show reduced VEGF-induced phosphorylation of KDR but not of FMS-like tyrosine kinase 1 (FLT1)/VEGF re
65 hESC-derived endoderm cells do not express KDR but, when cultured in media supporting hepatic diffe
67 hibition of VEGF or VEGF receptor 2 (VEGFR2)/KDR, but not VEGFR1/Flt-1, was sufficient to abrogate VE
69 or kinase insert domain-containing receptor (KDR) by associating with KDR and enhancing VEGF signalin
70 and endothelial cells)--Flk1 (also known as Kdr), c-Kit, and Nkx2-5, but not Brachyury--and subseque
73 nsert domain protein receptor, also known as Kdr) cardiovascular progenitor that represents one of th
74 phosphate transfer activity of the purified Kdr-CD required Mg2+ or Mn2+ and preactivation by adenos
75 me activity; optimized the concentrations of Kdr-CD, peptide and ATP substrates, and metal ions in th
76 e hematopoietic mesoderm and WNT-independent KDR(+)CD235a(+) primitive hematopoietic mesoderm reveale
77 me gene expression analyses on WNT-dependent KDR(+)CD235a(-) definitive hematopoietic mesoderm and WN
78 exclusively within definitive hematopoietic KDR(+)CD235a(-) mesoderm in a WNT- and fibroblast growth
80 identified as CD49f(H) CD41(H) (and c-Kit(D)KDR(+)CD42(+)CD9(++)CD31(+)) cells, expressing several h
81 B19V DNA concentrations were found in CD34(+)KDR(+) cells from 17 patients with chronic B19V-associat
82 s patients in the percentage of CD34+/CD133-/KDR+ cells costaining for OCN (5- and 2-fold, p < 0.001
84 simulating three scenarios of AngII-mediated KDR channel phosphorylation: (1), an increased steady st
85 ngiogenesis, and HIF-1alpha levels, and that KDR CNGs may be a useful biomarker for identifying patie
88 we assessed NSCLC cell lines and found that KDR CNGs were significantly associated with in vitro res
89 tion, and HIF-1alpha levels in cells bearing KDR CNGs, providing evidence for direct involvement of K
91 re than three times higher (P = .01) with MB(KDR) compared with control MBs and decreased significant
92 F165 rapidly and transiently increases ECSCR-KDR complex formation, a process blocked by the KDR tyro
97 rafts, interferes with VEGFR2 (also known as KDR) dimerization and signalling and inhibits vascular e
98 in shade avoidance; however, we propose that KDR does not interact with HFR1 to regulate shade avoida
100 Flt4, a receptor for Vegfc, cooperates with Kdr during artery morphogenesis, but not differentiation
102 esion contained a single somatic mutation in KDR (encodes VEGFR2), possibly in response to ramuciruma
103 3[G], OR=1.28; P=3.8 x 10(-11)), upstream of KDR encoding vascular endothelial growth factor receptor
104 d CD235a; 2) anti-CD144 (EC marker) and anti-KDR (EPC marker) conjugated-Q-dots exhibited the best se
105 der this condition, suggesting a role of the KDR-ERK1/2 pathway on endothelial cell proliferation.
107 del of lymphocyte trafficking, we found that KDR-expressing lymphocytes migrate into human skin in vi
108 ction of KDR on each T cell subset, and that KDR-expressing lymphocytes preferentially transmigrate a
109 cells were largely devoid of VE-cadherin and KDR expression and had a distinct FLT3(high)GATA3(low)RU
111 ng the 40 patients included in the analysis, KDR expression on IHC matched well with imaging signal o
113 he DH GRN through gata2 expression, then for kdr expression to enable the DH to respond to vascular e
114 using MBKDR is safe and allows assessment of KDR expression using immunohistochemistry (IHC) as the g
115 l oxygen environment and WT1, which enhances KDR expression, contribute to sex-specific Sox9 expressi
118 l growth factor (VEGF), and VEGF receptor-2 (KDR/Flk-1), Peroxisome proliferator-activated receptor g
119 endothelial cell-adhesion molecule-1, CD34, KDR/Flk-1, vascular endothelial cadherin, von Willebrand
120 EGF receptor-1 (VEGFR-1; Flt-1) and VEGFR-2 (KDR; Flk-1) (VEGFR(1-2)) in endothelial cells with a syn
124 mplex to cardiomyogenic loci in multipotent (KDR/Flk1+) progenitors, activating lineage-specific tran
126 ected is a target-site knock-down resistance kdr-form, on a background of generally elevated metaboli
127 d the association between alterations in the KDR gene and clinical outcome in patients with resected
130 riants in the Kinase Insert Domain Receptor (KDR) gene were strongly associated with significantly re
132 n upstream sequences of mouse flk1 and human kdr genes, suggesting that the regulatory machinery for
135 ave concluded that the knockdown resistance (kdr) genotype-phenotype correlation that is observed in
136 acing in mice provides in vivo evidence of a KDR+ hepatic progenitor for fetal hepatoblasts, adult he
142 These results provide evidence that a VEGF/KDR/HIF-1 alpha autocrine loop differentially mediates s
144 e the number of evolutionary origins of kdr, kdr-his and super-kdr, we sequenced a region of Vssc fro
146 ost on mosquitoes by reducing the ability of kdr homozygous A. gambiae sensu stricto to survive expos
150 st time define a novel function for VEGF and KDR in CD45RO+ memory T cell responses that are likely o
153 d to achieve prolonged inhibition of Kit and KDR in humans and which would therefore be expected to y
155 identified as potent inhibitors of VEGFR-2 (KDR) in both enzymatic and HUVEC cellular proliferation
157 In addition, a VEGF mutant, which binds only KDR, induced extracellular signal-regulated kinase (ERK)
160 n the basis of X-ray cocrystal structures of KDR inhibitors 34 (triazine) and 35 (nicotinamide).
168 latent polyadenylation site in intron 13 of KDR is activated by blocking the upstream 5' splicing si
170 ar endothelial growth factor (VEGF) receptor KDR is expressed on subsets of mitogen-activated CD4(+)
172 2 (VEGFR-2 or kinase insert domain receptor; KDR) is a known endothelial target also expressed in NSC
173 ing of EXEL-2880 to Met and VEGF receptor 2 (KDR) is characterized by a very slow off-rate, consisten
176 ermine the number of evolutionary origins of kdr, kdr-his and super-kdr, we sequenced a region of Vss
180 KDR tyrosine kinase inhibitor SU1498 or the KDR ligand VEGFA revealed that KDR signaling represses t
181 ish Vegf receptor-2 ortholog (referred to as kdr-like, kdrl) revealed surprisingly varied effects on
182 stem-cell-derived embryoid bodies generate a KDR(low)/C-KIT(CD117)(neg) population that displays card
183 When plated in monolayer cultures, these KDR(low)/C-KIT(neg) cells differentiate to generate popu
186 Mice lacking VEGFR2 in neurons (Nes-cre Kdr(lox/-)) show decreased dendritic arbors and spines a
188 lly, compound 16 was identified as a potent (KDR: < 1 nM and HUVEC: 4 nM) and selective inhibitor tha
193 nctions as a transcription factor, increased KDR mRNA levels, whereas the WT1(+KTS) isoform, which ac
195 enotyping revealed a high frequency of 1014F kdr mutation (82%) with significant difference in genoty
197 leucine to phenylalanine, termed the L-to-F kdr mutation, in the sodium channel of the insect nervou
199 ed PyR1 models explained recently discovered kdr mutations and predicted new deltamethrin-channel con
200 major role played by P450 in the absence of kdr mutations suggests that addition of the synergist PB
203 China found that both knockdown resistance (kdr) mutations and monooxygenase activity were significa
209 pha-activated ECs result in the induction of KDR on each T cell subset, and that KDR-expressing lymph
210 tions demonstrate that induced expression of KDR on subsets of T cells, and locally expressed VEGF, f
211 microbubble [MBKDR]) that is targeted at the KDR, one of the key regulators of neoangiogenesis in can
212 VEGF and its receptor VEGFR2 (also known as KDR or FLK1) are expressed in mouse hippocampal neurons
213 developing hippocampus VEGFR2 (also known as KDR or FLK1) is expressed specifically in the CA3 region
214 r and Flt1 in mouse retina, and depletion of Kdr or Flt1 blocked hypoxia-induced Src-PLD1-PKCgamma-cP
215 ine with these findings, depletion of either Kdr or Flt1 suppressed VEGFA-induced DNA synthesis, migr
219 a population of hESC-derived ROR2(+)/CD13(+)/KDR(+)/PDGFRalpha(+) cells that give rise to cardiomyocy
223 Here we report the successful generation of KDR(-)PDGFRalpha(+) progeny expressing paraxial mesoderm
224 and stellate cells by way of reduced VEGFR2 (KDR), phospholipase Cgamma (PLCgamma), and extracellular
225 g no effect on Flt1 phosphorylation, induced Kdr phosphorylation in human retinal microvascular endot
226 epresent an alternative way of activation of KDR/PLCgamma1 signaling besides KDR activation in angios
228 ucturally, vascular niches composed of c-kit-KDR-positive VPCs were identified within the walls of co
229 , CD34+/AC133+, CD34+/KDR+, and CD34+/AC133+/KDR+ progenitor cells was low in Eisenmenger patients co
230 formation of cardiomyocytes from multipotent Kdr(+) progenitors while promoting the differentiation o
235 ors and associated with significantly higher KDR protein and higher microvessel density than tumors w
236 positive genotype was associated with strong KDR protein expression and was restricted to the breast
237 de resistant population exhibited high 1014F kdr(R) allele frequencies (>60%) and RDL(R) (>80%) in co
239 locking VEGF-mediated signaling by the Flk-1/KDR receptor kinase inhibitor SU5416 significantly inhib
241 the distribution of the multiple origins of kdr resistance, finding unprecedented diversity in the D
244 ased or decreased colocalization of GFP with KDR/SFRP4 and CD31 in the regenerated diabetic wound bed
246 SU1498 or the KDR ligand VEGFA revealed that KDR signaling represses the testis-promoting gene Sox9 i
247 Neuropilin-1 (NRP-1)-mediated activation of KDR signaling through VEGF165 as a critical mechanism fo
250 ated signaling responses were inhibited by a KDR-specific small interfering RNA in a VEGF receptor-ex
251 ypothesis of multiple independent origins of kdr, super-kdr and kdr-his on an unprecedented geographi
252 ncy of ID2 in BMDCs led to downregulation of KDR, suppression of proangiogenic myeloid cells, and pre
254 h MBKDR is clinically feasible and safe, and KDR-targeted USMI signal matches well with KDR expressio
256 ntrast agent (kinase insert domain receptor [KDR] -targeted contrast microbubble [MBKDR]) that is tar
257 , regulating SMYD1 that activates HAND2, and KDR that with HAND2 orchestrates outflow tract formation
258 eptor targeting the VEGF receptor-2 (VEGFR2; KDR) that is overexpressed on tumor vasculature and T-ce
259 we report that WT1 stimulates expression of Kdr, the gene encoding VEGF receptor 2, in murine embryo
261 endothelial growth factor receptor-2 (VEGFR2/KDR) to a dominant-negative sKDR results in a strong ant
262 four times greater binding specificity of MB(KDR) to human KDR and cross-reactivity to murine VEGFR2
264 sodium channels confer knockdown resistance (kdr) to pyrethroids, the atomic mechanisms of pyrethroid
265 ce and contribution of knockdown resistance (kdr) to pyrethroids/DDT resistance observed in Anopheles
267 (CD34, CD133, kinase insert domain receptor [KDR]) to identify EPCs, we examined whether patients wit
270 -morpholino-mediated WT1 knockdown decreased Kdr transcripts in cultured embryonic gonads at multiple
271 complex formation, a process blocked by the KDR tyrosine kinase inhibitor compound SU5416 or inhibit
276 e kinases VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1/KDR), VEGF-B and PlGF bind to VEGFR-1 and not VEGFR-2.
278 s receptors, Flt-1/FLT-1 (VEGFR-1) and Flk-1/KDR (VEGFR-2), are key regulators of tumor angiogenesis
279 me "canalogenesis." Functional inhibition of KDR (VEGFR2), a critical receptor in initiating angiogen
281 nephron, whereas expression of its receptor (Kdr/Vegfr2) is largely restricted to adjacent peritubula
282 in chronic hypoxia (e.g. VEGFA, FLT1/VEGFR1, KDR/VEGFR2, BNIP3L, and SLC2A1/GLUT1), the function of w
283 biology and angiogenesis, such as TEK/Tie-2, KDR/VEGFR2, Tie-1, endothelial nitric oxide synthase and
284 usion between kinase insert domain receptor (KDR) (VEGFRII) and the PDGFRA gene, and six cases of PDG
285 racterized by the expression of VE-cadherin, KDR, von Willebrand factor, endothelial nitric oxide syn
286 the miR-200b gene targets ZEB1/2, GATA2, and KDR was confirmed by qRT-PCR as being lower in obese pat
288 erial-enhanced US imaging signal by using MB(KDR) was longitudinally measured during 6 days in tumors
289 scular endothelial growth-factor receptor 2 (KDR) was used, together with the stem cell antigen c-kit
290 olutionary origins of kdr, kdr-his and super-kdr, we sequenced a region of Vssc from house flies coll
291 ith rare likely loss-of-function variants in KDR were independently identified in the US PAH Biobank
293 pproach allowed us to independently validate KDR, which encodes for the Vascular Endothelial Growth F
294 , including Tlr7, Tlr9 and Nfkb1, as well as Kdr, which encodes the growth factor receptor VEGFR2.
295 atedly mutated genes identified by tNGS were KDR with different nonsynonymous mutations, MLL2 with di
296 , nor PlGF, induce the interaction of VEGFR2/KDR with IGF-1R, resulting in IGF-1R transactivation to
297 A heterodimeric peptide that binds to human KDR with low nanomolar affinity (K(D) = 0.5 nmol/L) was
298 nd to yield nanomolar inhibitors of VEGFR-2 (KDR) with an improved selectivity profile against a pane
299 ptor 2/kinase insert domain receptor (VEGFR2/KDR) with IGF-1R, which mediates the expression of TR3-T
300 shin revealed a somatic p.T771R mutation in KDR, without evidence of other somatic mutations or loss